NetworkNewsBreaks

ThursdayJan 28, 2021 10:41 am

NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in First Cohort of MS1819 Study

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, announced that it has completed patient enrollment in the first cohort of its Phase 2b OPTION 2 extension study. The study is evaluating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). In the announcement, the company noted that the Phase 2b OPTION 2 trial extension arm is dosing patients at sites in the United States and Europe; patients in this study previously participated in arms of the OPTION 2 trial. The ultimate objective of the MS1819 program…

Continue Reading

ThursdayJan 28, 2021 10:33 am

NetworkNewsBreaks – Loop Insights Inc. (TSX.V: MTRX) (OTCQB: RACMF) Appoints New Chief Technology Officer, New Director of Product and Innovation

Loop Insights (TSX.V: MTRX) (OTCQB: RACMF), a provider of contactless solutions and artificial intelligence ("AI") to drive real-time insights, enhanced customer engagement, and automated venue tracing to the brick-and-mortar space, has announced two new company officers. The company has named Tamer Shafik, former director of solution architecture at NTT DATA Corp of Japan, as its chief technology officer; that appointment will take effect Feb. 8, 2021. Also effective Feb. 8, 2021, is the appointment of Casey Matson-Dekay as Loop Insight’s new director of product and innovation. Before his three years at NTT Data, Shafik spent more than 15 year working in…

Continue Reading

ThursdayJan 28, 2021 10:11 am

NetworkNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Announces Preliminary Revenue Results

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights to publicly traded companies through its software-as-a-service (“SaaS”) platform, Sequire, has announced unaudited preliminary revenue results for Q4 and fiscal year 2020. According to the update, the company surpassed its guidance for the three months ended December 31, 2020, and expects to report net revenue of approximately $4.5 million. In addition, SRAX expects a 320% year-over-year revenue increase and 75% increase from Q3 2020, exceeding analyst expectations. “We continued to see significant demand for our Sequire platform in Q4 and this growth has continued into the first month…

Continue Reading

ThursdayJan 28, 2021 9:34 am

NetworkNewsBreaks – TAAT(TM) Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) (FRA: 2TP2) Launches Ad Campaign on Pump Displays at More Than 1,000 Gas Stations Throughout Ohio

TAAT(TM) Lifestyle & Wellness (CSE: TAAT) (OTCQB: TOBAF) (FRA: 2TP2) has announced a 60-day video ad campaign as part of its launch initiatives. The campaign will feature a 15-second ad targeting legal-aged smokers. The ad will be shown on a network of 10,442 gasoline pump displays at 1,087 chain and independent gas stations across Ohio. The company noted that the ad has been playing once every four minutes since Jan. 25, 2021, with 18.8 million impressions expected over the campaign’s two-month duration. The objective behind the campaign is to aggressively promote TAAT and increase awareness of the brand and product through…

Continue Reading

WednesdayJan 27, 2021 3:28 pm

NetworkNewsBreaks – Exro Technologies Inc. (TSX.V: EXRO) (OTCQB: EXROF) Names Audi Retired VP Terence Johnsson to Board

Exro Technologies (TSX.V: EXRO) (OTCQB: EXROF), a leading clean-technology company that has developed a new class of power electronics for electric motors and batteries, has announced that Terence Johnsson has joined its Board of Directors. An automotive executive with global experience, Johnsson is a retired vice president from Audi AG, General Motors and Volkswagen AG and has racked up more than three decades of professional sales experience at top levels of these large automotive manufacturers. After retiring, Johnsson turned his hand to supporting start-ups focused on implementing new technologies and reinventing sales channels for the emerging electric vehicle industry. Johnsson plans…

Continue Reading

WednesdayJan 27, 2021 3:13 pm

NetworkNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Signs Agreements to Acquire Leading Digital Musculoskeletal Company, Raise $70 Million Through Private Placement

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced that it has entered into a definitive agreement to acquire Upright Technologies Ltd., a digital musculoskeletal (“MSK”) company; the acquisition will be in the form of a stock transaction. The acquisition is designed to expand DarioHealth's multi-condition platform into the $213 billion musculoskeletal market and create one of the most comprehensive digital health platforms. The move also brings together complementary companies with industry-leading consumer engagement and clinical outcomes. In addition, DRIO has entered into definitive agreements with a group of health-care institutional investors to raise $70 million through a private…

Continue Reading

WednesdayJan 27, 2021 1:53 pm

NetworkNewsBreaks – Pure Extracts Technologies Corp.’s (CSE: PULL) (OTC: PRXTF) US Shares Gain DTC Eligibility

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF), a plant-based extraction company specializing in cannabis, hemp and mushroom products, this morning announced that its common shares on the OTC Market under the symbol "PRXTF" are now eligible for electronic clearing and settlement through The Depository Trust Company ("DTC"). “DTC eligibility is a major step forward in increasing liquidity, broadening our shareholder base and building a strong presence for our company within the US capital markets sphere. This is an important step in amplifying our story to a wider audience,” Pure Extracts CEO Ben Nikolaevsky stated in the news release. To view…

Continue Reading

WednesdayJan 27, 2021 1:34 pm

NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO to Present at Upcoming Virtual Investor Conference Small and Microcap Showcase

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s president and CEO Rodney Varner will present at the Virtual Investor Conference Small and Microcap Showcase at 11 AM ET on February 4, 2021. Varner will be providing a virtual company overview, including a synopsis of its diabetes gene therapy and details on the recent progress made on GNPX’s upcoming clinical trials for the treatment of non-small cell lung cancer. Following the conference, a replay of GNPX’s presentation will be available on the company’s website for…

Continue Reading

WednesdayJan 27, 2021 12:49 pm

NetworkNewsBreaks – Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) to Release Q3 Financial Results, Host Conference Call on February 10

Canopy Rivers (TSX: RIV) (OTC: CNPOF) today announced that it will be releasing its third quarter fiscal year 2021 financial results before markets open on February 10, 2021. Detailed information regarding the company’s financial statements for the three and nine months ended December 31, 2020 will be available on the company's profile on www.SEDAR.com and on the company's website at www.CanopyRivers.com/investors. The company will host a conference call and audio webcast following the release of its financial results at 9 AM ET on February 10. Canopy Rivers President and CEO Narbe Alexandrian, Chief Strategy Officer and General Counsel Matt Mundy and CFO Eddie Lucarelli will host the call. A live…

Continue Reading

WednesdayJan 27, 2021 12:21 pm

NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $4.1 Million

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed of its previously announced registered direct offering. The offering comprised 3,414,970 shares of POAI’s common stock, offered at a purchase price of $1.20 per share, which was priced at-the-market under Nasdaq rules. The announcement noted that gross proceeds from this offering for Predictive Oncology will total approximately $4.1 million, before fees and other offering expenses are deducted. POAI anticipates using net proceeds from the offering for working capital projects and purposes.  The company also announced a concurrent…

Continue Reading